Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Completed Phase 1 Interventional Results available

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

NCT00582543
View directory record Official record
Conditions
Prostate Cancer
Interventions
eMRI/MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 28, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217
View directory record Official record
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Withdrawn Phase 2 Interventional

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

NCT00694291
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818
View directory record Official record
Conditions
Elderly, Prostate Cancer
Interventions
LHRH Agonist Therapy Discontinuation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

NCT00078585
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC®-VF/TRICOM™
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
47
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793
View directory record Official record
Conditions
Prostate Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Hot Springs, Arkansas • Fort Meyers, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 28, 2026, 5:37 AM EDT
Terminated Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Enzalutamide, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed No phase listed Observational

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

NCT03896984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
Male only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

NCT00626548
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054, Palcebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

NCT02024178
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultrasound Imaging
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT05036226
View directory record Official record
Conditions
Prostate Cancer Recurrent, Solid Tumor, Adult
Interventions
Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00020735
View directory record Official record
Conditions
Prostate Cancer
Interventions
toremifene, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Joel Nelson, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Exploring the Potential of Robotic Telesurgery in Remote Settings

NCT07130708
View directory record Official record
Conditions
Prostate Carcinoma, Prostate Disease
Interventions
Telesurgery utilizing Microport Medbot Robotic Platform
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

NCT04751435
View directory record Official record
Conditions
Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
Cognitive interview, LCAM intervention, Standard of care
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT06616155
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Enzalutamide, Ruxolitinib
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

Impact of Acetazolamide in Reducing Referred Postoperative Pain

NCT04470843
View directory record Official record
Conditions
Prostate Cancer, Men
Interventions
Acetazolamide, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

NCT05751434
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions
Exercise Therapy
Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Internal Radiation Therapy in Treating Patients With Prostate Cancer

NCT00573833
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, quality-of-life assessment, brachytherapy
Other · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Early Phase 1 Interventional

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

NCT02415621
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Results available

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000
Drug · Radiation · Device
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 28, 2026, 5:37 AM EDT